Milestone cuts 20% of staff as Cardamyst sales hit $1M in Q3

Milestone Pharmaceuticals is cutting costs and staff following the FDA approval of its heart arrhythmia treatment, with two top executives departing the leadership team. The company said in its third-quarter earnings ...